Abstract

Purpose: This study aimed to determine the real-world prognostic significance of lymph node ratio (LNR) and log odds of positive lymph nodes (LOPLN) in patients with non-metastatic small bowel adenocarcinoma. Methods: Patients diagnosed with early-stage small bowel adenocarcinoma between January 2007 and December 2018 from a large Canadian province were identified. We calculated the LNR by dividing positive over total lymph nodes examined and the LOPLN as log ([positive lymph nodes + 0.5]/[negative lymph nodes + 0.5]). The LNR and LOPLN were categorized at cut-offs of 0.4 and −1.1, respectively. Multivariable Cox proportional hazards models were constructed for each nodal stage, LNR and LOPLN, adjusting for measured confounding factors. Harrell’s C-index and Akaike’s Information Criterion (AIC) were used to calculate the prognostic discriminatory abilities of the different models. Results: We identified 141 patients. The median age was 67 years and 54.6% were men. The 5-year overall survival rates for patients with stage I, II and III small bowel adenocarcinoma were 50.0%, 56.6% and 47.5%, respectively. The discriminatory ability was generally comparable for LOPLN, LNR and nodal stage in the prognostication of all patients. However, LOPLN had higher discriminatory ability among patients with at least one lymph node involvement (Harrell’s C-index, 0.75, 0.77 and 0.82, and AIC, 122.91, 119.68 and 110.69 for nodal stage, LNR and LOPLN, respectively). Conclusion: The LOPLN may provide better prognostic information when compared to LNR and nodal stage in specific patients.

Highlights

  • Introduction iationsSmall intestinal cancers comprise 0.6% of all new cancer diagnoses and 0.3% of all cancer deaths in the United States

  • Adenocarcinoma and neuroendocrine tumours represent the two most common histologies, each accounting for approximately 40% of small intestinal cancers, with the remainder largely consisting of lymphoma and sarcoma [2,3,4]

  • We identified 141 patients with non-metastatic small bowel cancer who were diagnosed and treated in Alberta from January 2007 to December 2018

Read more

Summary

Introduction

Small intestinal cancers comprise 0.6% of all new cancer diagnoses and 0.3% of all cancer deaths in the United States. 11,000 new diagnoses and 1700 deaths are expected in 2020 [1]. Adenocarcinoma and neuroendocrine tumours represent the two most common histologies, each accounting for approximately 40% of small intestinal cancers, with the remainder largely consisting of lymphoma and sarcoma [2,3,4]. Small bowel adenocarcinoma contributes to less than 5% of all cancers of the digestive tract [5]. The most frequent primary site is the duodenum (60%) followed by the jejunum (25%) and the ileum (15%) [6,7]. The prognosis of small bowel adenocarcinoma continues to be poor, with reported

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call